Introducing "Not So Different: a Podcast From The Center for Biosimilars"
In this innaugural episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.
The introduction of biosimilars into the US marketplace has been cause for both excitement and concern, as these products hold the potential to drive down costs and increase patient access, but face significant challenges to uptake. One of those challenges is interchangeability.
Federal law provides for interchangeable biosimilars, but the FDA has not yet granted that status to any biosimilar product, and hasn’t finalized its guidance on demonstrating interchangeability with a reference product. In this episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.
